Valeant Pharmaceuticals International (VRX) Downgraded by Vetr

Vetr cut shares of Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) from a strong-buy rating to a buy rating in a research note released on Monday. The firm currently has $19.18 target price on the specialty pharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on the company. BMO Capital Markets upped their price target on Valeant Pharmaceuticals International from $16.00 to $17.00 and gave the stock a market perform rating in a report on Monday, November 13th. ValuEngine cut Valeant Pharmaceuticals International from a buy rating to a hold rating in a report on Friday, September 1st. Royal Bank Of Canada decreased their price target on Valeant Pharmaceuticals International from $21.00 to $18.00 and set a sector perform rating for the company in a report on Friday, October 20th. Deutsche Bank set a $18.00 price target on Valeant Pharmaceuticals International and gave the stock a hold rating in a report on Thursday, November 16th. Finally, Cantor Fitzgerald restated a buy rating and issued a $23.00 price target on shares of Valeant Pharmaceuticals International in a report on Tuesday, August 29th. Five investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has an average rating of Hold and a consensus target price of $17.46.

Valeant Pharmaceuticals International (NYSE VRX) opened at $16.85 on Monday. The firm has a market capitalization of $6,096.87, a P/E ratio of 2.84, a price-to-earnings-growth ratio of 0.48 and a beta of -0.22. Valeant Pharmaceuticals International has a fifty-two week low of $8.31 and a fifty-two week high of $18.25. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03.

In other news, Director John Paulson purchased 344,216 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were acquired at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the transaction, the director now owns 94,559 shares in the company, valued at approximately $1,361,649.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 5.87% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of VRX. Dimensional Fund Advisors LP increased its position in Valeant Pharmaceuticals International by 327.6% in the third quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock worth $64,086,000 after buying an additional 3,426,410 shares during the period. Paulson & CO. Inc. grew its stake in shares of Valeant Pharmaceuticals International by 12.5% in the second quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock worth $377,372,000 after purchasing an additional 2,428,900 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Valeant Pharmaceuticals International in the second quarter worth $41,574,000. Canada Pension Plan Investment Board grew its stake in shares of Valeant Pharmaceuticals International by 24,953.6% in the second quarter. Canada Pension Plan Investment Board now owns 2,104,500 shares of the specialty pharmaceutical company’s stock worth $36,525,000 after purchasing an additional 2,096,100 shares in the last quarter. Finally, Cannell Peter B & Co. Inc. bought a new position in shares of Valeant Pharmaceuticals International in the second quarter worth $20,981,000. 49.49% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/07/valeant-pharmaceuticals-international-vrx-downgraded-by-vetr.html.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

What are top analysts saying about Valeant Pharmaceuticals International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Valeant Pharmaceuticals International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit